Last reviewed · How we verify
Fixed Combination Bimatoprost and Timolol
Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.
Bimatoprost is a prostaglandin analog that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Fixed Combination Bimatoprost and Timolol |
|---|---|
| Also known as | GANFORT® UD |
| Sponsor | Allergan |
| Drug class | Prostaglandin analog and beta-adrenergic receptor blocker |
| Target | Prostaglandin receptors and beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Bimatoprost works by binding to prostaglandin receptors in the eye, leading to increased outflow of aqueous humor and decreased intraocular pressure. Timolol, on the other hand, blocks beta-adrenergic receptors, reducing the production of aqueous humor and subsequently lowering intraocular pressure.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Eyelash growth
- Itching
- Redness of the eye
- Dry mouth
- Headache
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® (PHASE4)
- A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
- Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated (PHASE4)
- A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fixed Combination Bimatoprost and Timolol CI brief — competitive landscape report
- Fixed Combination Bimatoprost and Timolol updates RSS · CI watch RSS
- Allergan portfolio CI